Reformatting rituximab into human IgG2 and IgG4 isotypes dramatically improves apoptosis induction in vitro

PLoS ONE

Volumn 10, Issue 12, 2015, Pages

  Könitzer, Jennifer D ^a   Sieron, Annette ^a   Wacker, Angelika ^a   Enenkel, Barbara ^a  

^a BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYSTEINE; HYBRID PROTEIN; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2; IMMUNOGLOBULIN G4; IMMUNOGLOBULIN G4DM; IMMUNOGLOBULIN G4P; PROTEIN VARIANT; RITUXIMAB; UNCLASSIFIED DRUG; IMMUNOGLOBULIN G;

AMINO ACID SUBSTITUTION; ANTIBODY ENGINEERING; APOPTOSIS; ARTICLE; BURKITT LYMPHOMA CELL LINE; CH1 DOMAIN; CONTROLLED STUDY; DISULFIDE BOND; DRUG BINDING; DRUG CYTOTOXICITY; EC50; HEAVY CHAIN; HINGE REGION; HUMAN; HUMAN CELL; IN VITRO STUDY; MUTANT; PROTEIN DOMAIN; STRUCTURE ACTIVITY RELATION; AMINO ACID SEQUENCE; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; CHEMISTRY; DRUG EFFECTS; GENETICS; MOLECULAR GENETICS; PROTEIN ENGINEERING; PROTEIN TERTIARY STRUCTURE; TUMOR CELL LINE;

AMINO ACID SEQUENCE; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; APOPTOSIS; CELL LINE, TUMOR; HUMANS; IMMUNOGLOBULIN G; MOLECULAR SEQUENCE DATA; PROTEIN ENGINEERING; PROTEIN STRUCTURE, TERTIARY; RECOMBINANT FUSION PROTEINS; RITUXIMAB;

EID: 84957560299     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0145633     Document Type: Article

References (66)

1. Boross P, Leusen JH. Mechanisms of action of CD20 antibodies. Am J Cancer Res. 2012; 2(6):676-90. PMID: 23226614
2. Weiner GJ. Rituximab: mechanism of action. Semin Hematol. 2010 Apr; 47(2):115-23. doi: 10.1053/j. seminhematol.2010.01.011 PMID: 20350658
3. Johnson P, Glennie M. The mechanisms of action of rituximab in the elimination of tumor cells. Semin Oncol. 2003 Feb; 30(1 Suppl 2):3-8. PMID: 12652458
4. Maloney DG. Mechanism of action of rituximab. Anticancer Drugs. 2001 Jun; 12 Suppl 2:S1-S4. PMID: 11508930
5. Cartron G, Watier H, Golay J, Solal-Celigny P. From the bench to the bedside: ways to improve rituximab efficacy. Blood. 2004 Nov 1; 104(9):2635-42. PMID: 15226177
6. Ludwig DL, Pereira DS, Zhu Z, Hicklin DJ, Bohlen P. Monoclonal antibody therapeutics and apoptosis. Oncogene. 2003 Dec 8; 22(56):9097-106. PMID: 14663488
7. Cardarelli PM, Quinn M, Buckman D, Fang Y, Colcher D, King DJ, et al. Binding to CD20 by anti-B1 antibody or F(ab')(2) is sufficient for induction of apoptosis in B-cell lines. Cancer Immunol Immunother. 2002 Mar; 51(1):15-24. PMID: 11845256
8. Shan D, Ledbetter JA, Press OW. Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies. Blood. 1998 Mar 1; 91(5):1644-52. PMID: 9473230
9. Deans JP, Li H, Polyak MJ. CD20-mediated apoptosis: signalling through lipid rafts. Immunology. 2002 Oct; 107(2):176-82. PMID: 12383196
10. Deans JP, Schieven GL, Shu GL, Valentine MA, Gilliland LA, Aruffo A, et al. Association of tyrosine and serine kinases with the B cell surface antigen CD20. Induction via CD20 of tyrosine phosphorylation and activation of phospholipase C-gamma 1 and PLC phospholipase C-gamma 2. J Immunol. 1993 Nov 1; 151(9):4494-504. PMID: 7691952
11. Chan HT, Hughes D, French RR, Tutt AL, Walshe CA, Teeling JL, et al. CD20-induced lymphoma cell death is independent of both caspases and its redistribution into triton X-100 insoluble membrane rafts. Cancer Res. 2003 Sep 1; 63(17):5480-9. PMID: 14500384
12. Semac I, Palomba C, Kulangara K, Klages N, van Echten-Deckert G, Borisch B, et al. Anti-CD20 therapeutic antibody rituximab modifies the functional organization of rafts/microdomains of B lymphoma cells. Cancer Res. 2003 Jan 15; 63(2):534-40. PMID: 12543813
13. Hofmeister JK, Cooney D, Coggeshall KM. Clustered CD20 induced apoptosis: src-family kinase, the proximal regulator of tyrosine phosphorylation, calcium influx, and caspase 3-dependent apoptosis. Blood Cells Mol Dis. 2000 Apr; 26(2):133-43. PMID: 10753604
14. Byrd JC, Kitada S, Flinn IW, Aron JL, Pearson M, Lucas D, et al. The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction. Blood. 2002 Feb 1; 99(3):1038-43. PMID: 11807010
15. van der Kolk LE, Evers LM, Omene C, Lens SM, Lederman S, van Lier RA, et al. CD20-induced B cell death can bypass mitochondria and caspase activation. Leukemia. 2002 Sep; 16(9):1735-44. PMID: 12200688
16. Alduaij W, Ivanov A, Honeychurch J, Cheadle EJ, Potluri S, Lim SH, et al. Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies. Blood. 2011 Apr 28; 117(17):4519-29. doi: 10.1182/blood-2010-07-296913 PMID: 21378274
17. Ivanov A, Beers SA, Walshe CA, Honeychurch J, Alduaij W, Cox KL, et al. Monoclonal antibodies directed to CD20 and HLA-DR can elicit homotypic adhesion followed by lysosome-mediated cell death in human lymphoma and leukemia cells. J Clin Invest. 2009 Aug; 119(8):2143-59. doi: 10.1172/JCI37884 PMID: 19620786
18. Honeychurch J, Alduaij W, Azizyan M, Cheadle EJ, Pelicano H, Ivanov A, et al. Antibody-induced nonapoptotic cell death in human lymphoma and leukemia cells is mediated through a novel reactive oxygen species-dependent pathway. Blood. 2012 Apr 12; 119(15):3523-33. doi: 10.1182/blood-2011-12-395541 PMID: 22354003
19. Carter PJ. Potent antibody therapeutics by design. Nat Rev Immunol. 2006 May; 6(5):343-57. PMID: 16622479
20. Jefferis R. Antibody therapeutics: isotype and glycoform selection. Expert Opin Biol Ther. 2007 Sep; 7 (9):1401-13. PMID: 17727329
21. Salfeld JG. Isotype selection in antibody engineering. Nat Biotechnol. 2007 Dec; 25(12):1369-72. PMID: 18066027
22. Jefferis R. Isotype and glycoform selection for antibody therapeutics. Arch Biochem Biophys. 2012 Oct 15; 526(2):159-66. doi: 10.1016/j.abb.2012.03.021 PMID: 22465822
23. Holland M, Hewins P, Goodall M, Adu D, Jefferis R, Savage CO. Anti-neutrophil cytoplasm antibody IgG subclasses in Wegener's granulomatosis: a possible pathogenic role for the IgG4 subclass. Clin Exp Immunol. 2004 Oct; 138(1):183-92. PMID: 15373923
24. Niwa R, Natsume A, Uehara A, Wakitani M, Iida S, Uchida K, et al. IgG subclass-independent improvement of antibody-dependent cellular cytotoxicity by fucose removal from Asn297-linked oligosaccharides. J Immunol Methods. 2005 Nov 30; 306(1-2):151-60. PMID: 16219319
25. Kubota T, Niwa R, Satoh M, Akinaga S, Shitara K, Hanai N. Engineered therapeutic antibodies with improved effector functions. Cancer Sci. 2009 Sep; 100(9):1566-72. doi: 10.1111/j.1349-7006.2009. 01222.x PMID: 19538497
26. Moore GL, Chen H, Karki S, Lazar GA. Engineered Fc variant antibodies with enhanced ability to recruit complement and mediate effector functions. MAbs. 2010 Mar; 2(2):181-9. PMID: 20150767
27. Kellner C, Derer S, Valerius T, Peipp M. Boosting ADCC and CDC activity by Fc engineering and evaluation of antibody effector functions. Methods. 2014 Jan 1; 65(1):105-13. doi: 10.1016/j.ymeth.2013.06. 036 PMID: 23851282
28. Kaneko E, Niwa R. Optimizing therapeutic antibody function: progress with Fc domain engineering. Bio-Drugs. 2011 Feb 1; 25(1):1-11. doi: 10.2165/11537830-000000000-00000 PMID: 21033767
29. Lazar GA, Dang W, Karki S, Vafa O, Peng JS, Hyun L, et al. Engineered antibody Fc variants with enhanced effector function. Proc Natl Acad Sci U S A. 2006 Mar 14; 103(11):4005-10. PMID: 16537476
30. Martin SJ, Reutelingsperger CP, McGahon AJ, Rader JA, van Schie RC, LaFace DM, et al. Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: inhibition by overexpression of Bcl-2 and Abl. J Exp Med. 1995 Nov 1; 182(5):1545-56. PMID: 7595224
31. Durocher Y, Loignon M, inventors; Process, Vectors and Engineered Cell Lines for Enhanced Large-Scale Transfection.US 2011/0039339 A1. 2009.
32. Sambrook J, Russell DW. Molecular Cloning. Cold Spring Harbour Laboratory Press; 2001.
33. Braman J, Papworth C, Greener A. Site-directed mutagenesis using double-stranded plasmid DNA templates. Methods Mol Biol. 1996; 57:31-44. PMID: 8849992
34. Edelman GM, Cunningham BA, Gall WE, Gottlieb PD, Rutishauser U, Waxdal MJ. The covalent structure of an entire gammaG immunoglobulin molecule. Proc Natl Acad Sci U S A. 1969 May; 63(1):78-85. PMID: 5257969
35. Pace CN, Vajdos F, Fee L, Grimsley G, Gray T. How to measure and predict the molar absorption coefficient of a protein. Protein Sci. 1995 Nov; 4(11):2411-23. PMID: 8563639
36. Robertson MJ, Cochran KJ, Cameron C, Le JM, Tantravahi R, Ritz J. Characterization of a cell line, NKL, derived from an aggressive human natural killer cell leukemia. Exp Hematol. 1996 Feb; 24 (3):406-15. PMID: 8599969
37. von Pawel-Rammingen U, Johansson BP, Bjorck L. IdeS, a novel streptococcal cysteine proteinase with unique specificity for immunoglobulin G. EMBO J. 2002 Apr 2; 21(7):1607-15. PMID: 11927545
38. Rettig WJ, Garin-Chesa P, Healey JH, Su SL, Ozer HL, Schwab M, et al. Regulation and heteromeric structure of the fibroblast activation protein in normal and transformed cells of mesenchymal and neuroectodermal origin. Cancer Res. 1993 Jul 15; 53(14):3327-35. PMID: 8391923
39. Scott AM, Wiseman G, Welt S, Adjei A, Lee FT, Hopkins W, et al. A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer. Clin Cancer Res. 2003 May; 9(5):1639-47. PMID: 12738716
40. Lichtenfels R, Biddison WE, Schulz H, Vogt AB, Martin R. CARE-LASS (calcein-release-assay), an improved fluorescence-based test system to measure cytotoxic T lymphocyte activity. J Immunol Methods. 1994 Jun 24; 172(2):227-39. PMID: 7518485
41. Angal S, King DJ, Bodmer MW, Turner A, Lawson AD, Roberts G, et al. A single amino acid substitution abolishes the heterogeneity of chimeric mouse/human (IgG4) antibody. Mol Immunol. 1993 Jan; 30 (1):105-8. PMID: 8417368
42. Reddy MP, Kinney CA, Chaikin MA, Payne A, Fishman-Lobell J, Tsui P, et al. Elimination of Fc receptor-dependent effector functions of a modified IgG4 monoclonal antibody to human CD4. J Immunol. 2000 Feb 15; 164(4):1925-33. PMID: 10657642
43. Brekke OH, Michaelsen TE, Sandlie I. The structural requirements for complement activation by IgG: does it hinge on the hinge? Immunol Today. 1995 Feb; 16(2):85-90. PMID: 7888072
44. Cai Q, Westin J, Fu K, Desai M, Zhang L, Huang H, et al. Accelerated therapeutic progress in diffuse large B cell lymphoma. Ann Hematol. 2014 Apr; 93(4):541-56. doi: 10.1007/s00277-013-1979-7 PMID: 24375125
45. Wildes TM, Farrington L, Yeung C, Harrington AM, Foyil KV, Liu J, et al. Rituximab is associated with improved survival in Burkitt lymphoma: a retrospective analysis from two US academic medical centers. Ther Adv Hematol. 2014 Feb; 5(1):3-12. doi: 10.1177/2040620713514682 PMID: 24490019
46. Peipp M, van de Winkel JG, Valerius T. Molecular engineering to improve antibodies' anti-lymphoma activity. Best Pract Res Clin Haematol. 2011 Jun; 24(2):217-29. doi: 10.1016/j.beha.2011.03.004 PMID: 21658620
47. van MT, Hagenbeek A. CD20-targeted therapy: the next generation of antibodies. Semin Hematol. 2010 Apr; 47(2):199-210. doi: 10.1053/j.seminhematol.2010.01.007 PMID: 20350667
48. Glennie MJ, French RR, Cragg MS, Taylor RP. Mechanisms of killing by anti-CD20 monoclonal antibodies. Mol Immunol. 2007 Sep; 44(16):3823-37. PMID: 17768100
49. Mossner E, Brunker P, Moser S, Puntener U, Schmidt C, Herter S, et al. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Blood. 2010 Jun 3; 115(22):4393-402. doi: 10.1182/blood-2009-06-225979 PMID: 20194898
50. Teeling JL, French RR, Cragg MS, van den Brakel J, Pluyter M, Huang H, et al. Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood. 2004 Sep 15; 104(6):1793-800. PMID: 15172969
51. Klein C, Lammens A, Schafer W, Georges G, Schwaiger M, Mossner E, et al. Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties. MAbs. 2013 Jan; 5(1):22-33. doi: 10.4161/mabs.22771 PMID: 23211638
52. Teeling JL, Mackus WJ, Wiegman LJ, van den Brakel JH, Beers SA, French RR, et al. The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. J Immunol. 2006 Jul 1; 177(1):362-71. PMID: 16785532
53. McCloskey N, Turner MW, Steffner P, Owens R, Goldblatt D. Human constant regions influence the antibody binding characteristics of mouse-human chimeric IgG subclasses. Immunology. 1996 Jun; 88 (2):169-73. PMID: 8690447
54. Roux KH, Strelets L, Michaelsen TE. Flexibility of human IgG subclasses. J Immunol. 1997 Oct 1; 159 (7):3372-82. PMID: 9317136
55. Dangl JL, Wensel TG, Morrison SL, Stryer L, Herzenberg LA, Oi VT. Segmental flexibility and complement fixation of genetically engineered chimeric human, rabbit and mouse antibodies. EMBO J. 1988 Jul; 7(7):1989-94. PMID: 3138110
56. Oi VT, Vuong TM, Hardy R, Reidler J, Dangle J, Herzenberg LA, et al. Correlation between segmental flexibility and effector function of antibodies. Nature. 1984 Jan 12; 307(5947):136-40. PMID: 6690993
57. Rayner LE, Hui GK, Gor J, Heenan RK, Dalby PA, Perkins SJ. The Fab conformations in the solution structure of human IgG4 restricts access to its Fc region: implications for functional activity. J Biol Chem. 2014 May 29; 289(30):20740-56. doi: 10.1074/jbc.M114.572404 PMID: 24876381
58. Niederfellner G, Lammens A, Mundigl O, Georges GJ, Schaefer W, Schwaiger M, et al. Epitope characterization and crystal structure of GA101 provide insights into the molecular basis for type I/II distinction of CD20 antibodies. Blood. 2011 Jul 14; 118(2):358-67. doi: 10.1182/blood-2010-09-305847 PMID: 21444918
59. Hagihara Y, Saerens D. Engineering disulfide bonds within an antibody. Biochim Biophys Acta. 2014 Jul 17; 1844(11):2016-23. doi: 10.1016/j.bbapap.2014.07.005 PMID: 25038323
60. Lightle S, Aykent S, Lacher N, Mitaksov V, Wells K, Zobel J, et al. Mutations within a human IgG2 antibody form distinct and homogeneous disulfide isomers but do not affect Fc gamma receptor or C1q binding. Protein Sci. 2010 Apr; 19(4):753-62. doi: 10.1002/pro.352 PMID: 20120022
61. Liu H, May K. Disulfide bond structures of IgG molecules: structural variations, chemical modifications and possible impacts to stability and biological function. MAbs. 2012 Jan; 4(1):17-23. doi: 10.4161/mabs.4.1.18347 PMID: 22327427
62. White AL, Chan HT, French RR, Willoughby J, Mockridge CI, Roghanian A, et al. Conformation of the human immunoglobulin G2 hinge imparts superagonistic properties to immunostimulatory anticancer antibodies. Cancer Cell. 2015 Jan 12; 27(1):138-48. doi: 10.1016/j.ccell.2014.11.001 PMID: 25500122
63. Cragg MS. CD20 antibodies: doing the time warp. Blood. 2011 Jul 14; 118(2):219-20. doi: 10.1182/blood-2011-04-346700 PMID: 21757627
64. Niwa R, Sakurada M, Kobayashi Y, Uehara A, Matsushima K, Ueda R, et al. Enhanced natural killer cell binding and activation by low-fucose IgG1 antibody results in potent antibody-dependent cellular cytotoxicity induction at lower antigen density. Clin Cancer Res. 2005 Mar 15; 11(6):2327-36. PMID: 15788684
65. Iida S, Kuni-Kamochi R, Mori K, Misaka H, Inoue M, Okazaki A, et al. Two mechanisms of the enhanced antibody-dependent cellular cytotoxicity (ADCC) efficacy of non-fucosylated therapeutic antibodies in human blood. BMC Cancer. 2009; 9:58. doi: 10.1186/1471-2407-9-58 PMID: 19226457
66. Lazar GA, Dang W, Karki S, Vafa O, Peng JS, Hyun L, et al. Engineered antibody Fc variants with enhanced effector function. Proc Natl Acad Sci U S A. 2006 Mar 14; 103(11):4005-10. PMID: 16537476